12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Diclofenac regulatory update

EMA's Co-ordination Group for Mutual Recognition and Decentralised Procedures (CMDh) endorsed a recommendation from EMA's Pharmacovigilance Risk Assessment Committee (PRAC) that pain and inflammation drug diclofenac receive the same precautions in effect to minimize the risks...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >